KRRO vs. HRTX, BMEA, ANNX, LXRX, NGNE, MRSN, CRBP, ESPR, PEPG, and RVNC
Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Heron Therapeutics (HRTX), Biomea Fusion (BMEA), Annexon (ANNX), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Heron Therapeutics (NASDAQ:HRTX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Korro Bio has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 95.73%. Korro Bio has a consensus price target of $126.25, indicating a potential upside of 152.25%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Korro Bio is more favorable than Heron Therapeutics.
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 6.4% of Heron Therapeutics shares are owned by company insiders. Comparatively, 16.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Heron Therapeutics received 647 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 68.98% of users gave Heron Therapeutics an outperform vote.
Korro Bio has a net margin of 0.00% compared to Korro Bio's net margin of -61.28%. Korro Bio's return on equity of 0.00% beat Heron Therapeutics' return on equity.
In the previous week, Heron Therapeutics had 9 more articles in the media than Korro Bio. MarketBeat recorded 14 mentions for Heron Therapeutics and 5 mentions for Korro Bio. Heron Therapeutics' average media sentiment score of 0.89 beat Korro Bio's score of 0.55 indicating that Korro Bio is being referred to more favorably in the news media.
Heron Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.
Summary
Korro Bio beats Heron Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Korro Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Korro Bio Competitors List
Related Companies and Tools
